BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise BNT327, BioNTech’s bispecific antibody, to treat multiple solid tumour types. BNT327 targets two established immuno-oncology pathways, PD-L1 and VEGF-A, to enhance tumour targeting and modulate the tumour microenvironment. It is currently in phase 3 trials for small cell and non-small […]
The post BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumours appeared first on Pharmafile.
